thesi expect revenu growth reacceler edward
benefit approv transcathet aortic valv replac tavr
low-risk patient new product launch particularli pascal
transcathet mitral valv repair tmvr system pascal receiv eu
approv februari posit data ce mark trial
support uptak rais adjust net incom
price target
new product launch indic support growth
edward remain best place benefit long-term structur growth
opportun offer transcathet valv repair replac expect
revenu growth re-acceler report highlight potenti
edward pascal tmvr devic compani present strong clinic data
europcr congress pari may potenti re-acceler
tavr market growth follow robust low-risk data
trial updat forecast mitral valv repair opportun estim
organ revenu growth adjust ep
compound-annual-growth-rate amongst highest global sector
fig summari estim valuat metric
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
expect tavr market edward market leader reach
compound-annual-growth-rate edward tavr organ revenu growth
slow howev expect growth reacceler
remaind support launch sapien ultra us europ
low-risk approv reiter belief demand tavr
procedur like continu show double-digit growth mani year show
global tavr opportun market estim fig
mitral revenu support growth acceler
perform also support acceler growth compani
nascent portfolio transcathet mitral tricuspid therapi transcathet
mitral valv therapi tmvt market repair replac still immatur
edward industri particip given initi guidanc
transcathet mitral tricuspid valv repair replac market reach
market worth abbott us
mitraclip repair product account sale
posit edward gain ce mark approv mitral repair devic pascal
februari subsequ began initi roll-out europ edward also
gain approv start us trial pascal patient primari mitral
regurgit mr clasp iid us trial pascal degen mr
enrol clasp iif trial function mr expect start enrol
late tricuspid earli feasibl studi ef also enrol
highlight breadth edward transcathet mitral valv portfolio fig
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
fig edward transcathet mitral tricuspid portfolio
mitral valv repair develop promis
literatur suggest number peopl suffer mr
number aortic stenosi implic potenti size mitral
repair/ replac market may potenti aortic valv
replac due cours note model tavr market
opportun mitral regurgit mr either primari valv diseas
degen secondari function left ventricular dysfunct affect
million american almost one ten peopl age
preval diseas expect doubl next decad
sever symptomat aortic stenosi mitral valv diseas poor
prognosi mortal within one year diagnosi patient moder
sever mr mortal five year
unlik open surgic valv replac strong outcom
patient mr oper surgic mitral valv replac
complex procedur aortic valv surgeri rel poor outcom
retic surgeon perform open heart mitral valv repair replac
underlin fact surgic treatment mitral
tricuspid regurgit tr us fig million patient
moder sever mr deem elig treatment accord
fda guidelin approxim high risk surgeri
remaind refer surgeri eurointervent volume
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
fig us patient mr tr undergo surgic intervent
patient
moder sever mr
tr
consid rel poor result open surgeri mitral valv diseas rel
aortic valv replac wider health effect open-heart mr
surgeri expect transcathet approach avoid invas surgeri
cardiopulmonari bypass continu gain accept surgic commun
abbott mitraclip account almost tmvr sale date
appetit transcathet solut mitral valv diseas highlight
success abbott mitraclip devic fig
mitraclip design reduc mr edge-to-edg repair use clip
approxim two leaflet mitral valv thu form double-orific valv
fig reduc mr manufactur cobalt chrome polyest cover
design promot tissu growth mri-saf posit use
femor access beat heart procedur enabl faster recoveri reduc hospit
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
fig mitral valv leaflet attach mitraclip
mitraclip fda approv us market octob europ
first transcathet altern mitral valv surgeri remain
transcathet devic approv treatment mitral repair us market
commerci approv transcathet mitral valv replac implant
guidelin direct medic therapi gdmt cardiac resynchronis therapi
crt provid symptomat relief dont treat underli condit
mitraclip seen strong uptak sinc launch follow sale
grew mitraclip approv patient
symptomat degen also known primari mr prohibit risk
mitral-valv surgeri approv base registri data endovascular valv
potenti mitral valv repair confirm coapt trial
potenti tmvr treat mr cement strong result
achiev coapt cardiovascular outcom assess mitraclip
percutan therapi heart failur patient function mitral
regurgit trial present septemb transcathet
cardiovascular tct meet trial design assess
safeti efficaci transcathet mitral valv repair use mitraclip heart failur
patient secondari mr remain symptomat despit gdmt trial use
medic therapi control arm rather surgeri sinc patient
function mr histor treat surgic
month follow-up total number hospit group treat
mitraclip compar control group gdmt repres
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
annualis rate compar control group per patient
year statist signific result rate freedom devic relat
complic month well object perform goal
primari safeti endpoint all-caus mortal month also
statist significantli lower mitraclip gdmt medic therapi
alon versu addit qualiti life assess
kccq determin nyha function class significantli better
function capac six-minut walk test preserv mitral
regurgit left ventricular remodel measur mr grade left
ventricular end-diastol volum less sever device-bas treatment
medic therapi alon
posit result coapt import prior coapt
substanti debat amongst clinician valu mitral valv repair use
clip treat mr partial result mix clinic data exampl
us trial everest ii mitraclip shown safer open heart
mitral valv repair also effect reduc sever mr
strong coapt data appear immedi effect tmvr demand
abbott confer call manag disclos mitraclip revenu grew
yoy
fda approv secondari mitral regurgit expand market
mitraclip growth date despit regulatori approv fraction
total mr market devic initi approv treatment
degen mr thu limit patient popul degen also known
primari mitral valv diseas result failur valv usual caus
flail valv leaflet ruptur chorda caus leaflet becom partial
march fda approv mitraclip treatment secondari mr
secondari function mr caus enlarg heart mitral valv
heart attack heart failur weaken left ventricl result
dilat mitral valv annulu papillari muscl displac reduc
abil mitral valv close properli result mitral regurgit
mitraclip use mr patient
europ despit mitraclip initi use also predominantli degen
patient mitraclip use function mr mortal function
patient approxim doubl degen mr
follow mitraclip fda approv function mr would expect similar
transit rapid growth mitraclip use function mr popul
nejm editori review coapt french mitraclip trial
mitra-fr author nishimura md robert bonow md highlight
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
potenti tmvr therapi use edge-to-edg repair techniqu also
import patient select note result suggest
approach appear effect patient truli refractori medic therapi
may case less sick patient
editor conclud edge-to-edg transcathet mitral-valv repair
perform experienc centr high degre success result
sustain reduct sever mitral regurgit whether translat
lower rate death hospit appear depend least part patient
editori note investig need identifi patient
greatest chanc benefit like determin
rel contribut mitral regurgit rather left ventricular
dysfunct patient clinic condit may possibl role
edge-to-edg repair patient moder sever mr medic therapi
fail
follow-up data present europcr coapt trial suggest
inde case
posit follow-up analysi publish pcr highlight mechan action
follow-up data coapt patient group show reduct mr
respons improv outcom mitraclip patient group rather
factor
saibal md present follow-up data late break trial session
europcr relationship residu mr clinic function outcom
coapt trial may better understand mechanist effect mr
reduct coapt investig pool mitraclip gdmt arm
analys outcom accord mr reduct primari
endpoint follow-up analysi time first heart failur hospit all-
caus deathand rate significantli higher among patient residu mr
higher compar patient left mr
mr
follow-up analysi show lower residu mr day strongli
associ reduc heart failur hospit all-caus mortal
improv qualiti life studi also show time gdmt
patient saw improv mr day improv much
durabl treat mitraclip result support surgeon
accept mr repair use edge-to-edg techniqu
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
current guidelin yet updat
accord aha/acc guidelin mitral valv repair class
recommend prefer surgic mitral valv replac patient
sever degen mr howev patient function mitral valv diseas
guidelin highlight surgic mitral valv replac
consid class iib altern gdmt aha guidelin yet
updat post fda approv mitraclip function mr march
europ procedur also recommend high-risk degen patient
also consid certain patient function mr
consid strong clinic data support use edge-to-edg mitral valv
repair guidelin yet updat european associ
percutan cardiovascular intervent eapci issu statement europcr
congress may support technolog use appropri select patient
europcr meet bernard pendergast st thoma hospit read
posit statement role transcathet edge-to-edg repair mitraclip pascal
manag heart failur secondari mitral regurgit posit
statement recommend earli referr symptomat heart failur
moder sever mr multidisciplinari heart team team evalu
optimis medic therapi consid role devic therapi transcathet
mitral intervent appropri surgeri
heart team consist valv intervent specialist valv surgeon heart
failur specialist valv imag specialist electrophysiologist pendergast
emphasis base result coapt transcathet edge-to-edg repair
appropri care select patient remain symptomat despit
optim treatment inclus criteria use select patient coapt trial
firmli adher allow judici evidence-bas applic
technolog
ce mark data suggest pascal competit
earli clinic data pascal encourag follow ce mark approv
februari edward initi devic roll-out europ
europcr congress pari may edward present six month
data european ce mark trial result show pascal effect
reduc mitral regurgit mr day patient achiev
reduct mr grade less mild/no mr grade less
still six month result slightli achiev coapt trial
patient grade mr prior procedur importantli
mitraclip benefit devic implant sustain day
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
pascal ce mark studi patient achiev grade less mr six
month maintain patient grade mr prior treatment
coapt trial day patient treat mitraclip achiev mr
grade less improv six month fig note
mitraclip patient coapt trial continu see mr improv
month surviv patient
fig pascal mitraclip mr reduct compar clasp coapt trial
pascal safeti also similar mitraclip all-caus mortal day
zero stroke rate death stroke mitraclip arm coapt
respect
patient treat pascal also benefit strong improv heart
function measur nyha new york heart associ index fig
fig pascal mitraclip improv heart function nyha class
note pascal clasp patient slightli better heart function
baselin nyha class compar coapt mitraclip patient
result directli compar howev improv
heart function reduct mr suggest pascal offer least
competit altern mitraclip
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
surgeon feedback suggest system easi use
data present dr konstantino spargia hygeia hospit athen like
mitraclip pascal devic design achiev edge-to-edg repair clip
two leaflet togeth reduc level mr howev sever differ
devic dr spargia suggest may make pascal system easier
use clasp devic allow independ leaflet captur one challeng
use mitraclip oper must captur valv leaflet
simultan may requir multipl attempt use pascal cardiologist
captur one leaflet move across captur leaflet dr spargia also
argu insert guid cathet easier master design
allow easier manoeuvr devic around valv
ask session chairman hendrik treed univers hospit bonn
els differenti devic compar mitraclip dr spargia also
highlight central spacer design help fill orific area broad
paddl design clip design reduc stress leaflet captur
note result produc oper zero close zero
experi devic underl mitraclip excel result
achiev rel limit experi
pascal devic receiv strong back number promin surgeon
includ dr marti leon lead investig trial dr leon
previous note pascal user said pascal
mitraclip easier use effect reduct mr
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
abbott claim patent infring
januari abbott file complaint district court delawar
edward pascal devic abbott sought preliminari injunct relief ground
patent infring accord file edward devic infring upon claim
relat five mitraclip patent
march court deni attempt februari abbott file temporari
restrain order edward move would prevent edward
manufactur pascal us court resolv abbott motion
preliminari injunct hear motion preliminari injunct took
place april edward state result expect favour
note uk judg deni ident bid injunct abbott
light litig howev edward agre limit pascal implant uk
procedur
us uk trial expedit court due take place
cardioband struggl
sale cardioband see fig edward transcathet mitral valv annuloplasti
devic remain limit due continu manufactur capac constraint solv
on-going issu site acquir cardioband develop valtech
purchas januari edward move manufactur locat
expect capac gradual improv
robust low-risk efficaci data support tavr market expans
pascal support materi acceler edward transcathet heart
valv therapi busi mid-term group perform continu
driven market-lead tavr franchis expect tavr sale growth
group revenu reacceler underli
support continu market expans low-risk
approv expect
all-caus mortal versu surgeri
edward lifesci report strong result trial
sapien transcathet aortic valv tavr american colleg cardiolog
meet march
risk death one year tavr group compar
surgeri trial primari composit endpoint death caus stroke
rehospit occur patient undergo tavr
patient treat surgeri show superior
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
secondari endpoint data also encourag perman pacemak
implant ppi rate well level seen
intermedi risk trial slightli rate surgic arm new
onset atrial fibril follow procedur also materi lower
surgic arm versu superior seen previou tavr trial patient
underw tavr also rapid improv nyha class six-
minut walk-test distanc kccq patient satisfact score
underw surgeri previou tavr trial length hospit stay shorter
among treat tavr bleed also significantli lower
surgic group
fig result evolut risk trial
sever ill st ave score
freedom heart failur nyha class
also report posit result evolut low-risk trial show
all-caus mortal disabl stroke one year versu surgic group
surgeon commentari underlin benefit appar class effect
combin evolut risk result expect approv
feedback receiv event underlin differ studi design
make direct comparison two trial difficult surgeon
suggest high pacemak implant rate pmi evolut trial
one year would concern surgeon given low-risk patient gener
younger note patient treat latest
valv evolut patient treat corevalv first
gener devic previous shown high pacemak implant rate
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
surgeon respons posit
initi respons intervent cardiologist confer
posit commentari meet follow result present
lead surgeon highlight expect tavr becom standard care
patient sever aortic stenosi
co-princip investig marti leon director center
intervent vascular therapi newyork-presbyterian/columbia note
trial demonstr result show tavr proven therapi sever
tavr consid prefer therapi low surgic risk
low-risk approv expect late
strong one-year low-risk data studi result low risk
commerci fda approv late posit data expect reflect
stock perform ahead data show sapien
statist superior primari secondari endpoint surgeri
expect strong uptak devic low-risk patient follow approv
expect low-risk approv help re-acceler market growth
patient sever symptomat defin low risk deem heart
team risk mortal follow standard heart valv surgeri
posit data confirm result sever previous publish trial tavr
would show superior open surgeri low-risk patient
intermedi sever risk patient includ medtron us trial support
intermedi risk approv surtavi nordic aortic valv intervent
notion trial first trial randomis patient sever aortic valv
stenosi either tavr savr
princip investig wrote nejm conclus
report find low-risk patient suggest valu tavr compar
surgeri may independ risk profil
tavr growth support sapien ultra centera roll-out
growth also support ramp-up sale edward recent
tavr valv sapien ultra centera sapien ultra approv europ
mid-novemb us decemb
edward continu roll-out sapien ultra valv europ target
control roll-out includ train ensur high procedur success new
system call manag note ultra centera valv
minim effect result acceler sale valv
support european perform remaind year
ultra system differ sapien less step procedur
ultra valv pre-mount balloon rather surgeon align
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
balloon valv aorta also axela sheath benefit dynam
expans contract design reduc vascular complic novel
design benefit addit train
sapien ultra also taller skirt around valv design reduc
paravalvular leak skirt also made differ materi polyethylen
terephthal promot tissu in-growth
centera edward next gener tavr system reposition benefit
enhanc deliveri system flex mechan trackabl improv
devic align well user-control motor handl clinic data
centera consist strong show best-in-class level pacemak
implant rate tavr devic date data ce mark studi show
all-caus mortal one-year disabl stroke rate
new perman pacemak implant pmi rate result
compar well result trial current devic result suggest
edward current avail data best class tavr devic european
market measur mortal improv heart function reduct
paravalvular leak day importantli lowest pmi rate
devic date
expect devic strengthen ew market posit enabl better retain
european market share despit increas competit boston
scientif us trial centera set complet enrol
medicar announc long-await new transcathet aortic valv
replac tavr nation coverag determin ncd slightli
relax prerequisit hospit provid tavr servic includ patient
evalu surgeon volum facil infrastructur requir major
chang expect final remov risk potenti cut coverag
propos new guidelin medicar state propos modif
hospit heart team oper volum requir reflect intent strike
balanc ensur hospit experi capabl handl
complex structur heart diseas case limit burden barrier
unnecessari requir may hospit patient
earli tavr trial could support use asymptomat patient
half develop asymptomat show outward sign
diseas faint chest pain current standard care
patient activ surveil howev patient deterior quickli
record indic patient diagnos asymptomat still
requir form cardiovascular intervent within two year
edward explor potenti tavr use asymptomat patient
earli tavr trial decemb trial enrol target
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
patient popul us hospit trial randomis
tavr clinic surveil primari endpoint superior two-year
composit all-caus mortal stroke unplan cardiovascular hospit
us
trial follow-up design address concern durabl
investig highlight conclus nejm articl
import limit trial doesnt address concern
potenti long-term structur valv deterior howev unlik
predecessor trial patient trial follow least
year year evolut patient also follow
year compani thu acknowledg arguabl materi
remain concern caus surgeon refrain adopt tavr standard
care surgeri
latest data still suggest littl durabl risk compar surgic devic
sever studi address long-term durabl concern around tavr
present europcr intervent cardiolog congress pari may
data continu suggest evid long-term valv durabl
differ significantli surgic bioprosthet valv
exampl team st paul hospit vancouv led john webb one
pioneer tavr surgeri present follow-up patient treat
tavi team treat patient patient surviv
ten year patient still show regular valv function ten year
three sever valv deterior encourag data particularli
consid patient receiv first gener devic time tavr
approv patient deem high risk inoper open surgeri
notabl two patient st paul studi success re-intervent
one surgeri one receiv latest gener valv sapien valve-in-
import note inform cover standard regulatori disclosur
